Participants needed for Gilenya Trial
The Lynn Health Science Institute in Oklahoma City is conducting a 6-month randomized, active comparator, open labeled study to evaluate patient outcomes, safety and tolerability of Gilenya(fingolimod) 0.5mg in individuals with relapsing forms of multiple sclerosis who are candidates for MS therapy change from previous disease modifying therapies. Participants must be 18-65 years of age. Individuals with secondary progressive forms of MS will also be considered for participation in the research trial.
Gilenya is currently the first and only approved oral medication for multiple sclerosis. Trial participants will have no placebo, and all study related tests are provided and paid for by the study. The Principal Investigator for the trial is Mark Fisher, MD, a board certified Neurologist.
If interested, please contact Jessica Tirado, LPN, Certified Clinical Research Coordinator for the Lynn Health Science Institute. She may be reached at firstname.lastname@example.org or 405-602-3921.